CLINICAL_TRIALS
trial_result
· 2016-03-17
Clinical Trial Update: Ponatinib for Advanced Medullary Thyroid Cancer [Phase 2]
Summary
A Phase 2 trial of ponatinib for advanced medullary thyroid carcinoma was terminated, with results posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Thyroid Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2016-03-17